Pentoxifylline: a cheap substitute for anti-TNFα agents?;Pentoxifylline : l'anti-TNF du pauvre ?

Revue de Medecine Interne

Volumn 27, Issue 5, 2006, Pages 400-405

  Koenig, M ^a,b   Cathebras P ^b   Guy, C ^c   Rousset, H ^d  

^a NOTRE DAME HOSPITAL   (Canada)

^b HÔPITAL NORD   (France)

^c SERVICE DE NEUROLOGIE   (France)

^d CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

Inflammatory diseases; Pentoxifylline; TNF

Indexed keywords

AMIFOSTINE; AZATHIOPRINE; CIPROFLOXACIN; COLCHICEINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; IMMUNOGLOBULIN; MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT; PENTOXIFYLLINE; PREDNISOLONE; PREDNISONE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; PHOSPHODIESTERASE INHIBITOR;

ALCOHOL LIVER DISEASE; ANTIINFLAMMATORY ACTIVITY; BEHCET DISEASE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG SUBSTITUTION; ENTERITIS; GASTROINTESTINAL SYMPTOM; GLOMERULONEPHRITIS; GRANULOMATOSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LUPUS ERYTHEMATOSUS NEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; MONOTHERAPY; PROTEINURIA; REMISSION; SARCOIDOSIS; SHORT SURVEY; SYSTEMIC LUPUS ERYTHEMATOSUS; DRUG ANTAGONISM; REVIEW; VASCULAR DISEASE;

CLINICAL TRIALS; HUMANS; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR DISEASES;

EID: 33646487016     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2005.09.020     Document Type: Short Survey

References (35)

1. Hood S.C., Moher D., and Barber G.G. Management of intermittent claudication with pentoxifylline : meta-analysis of randomized controlled trials. CMAJ 156 (1997) 765-767
2. Girolami B., Bernardi E., Prins M.H., Ten Cate J.W., Hetteriachchi R., Prandoni P., et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch. Intern. Med. 159 (1999) 337-345
3. Moher D., Pham B., Ausejo M., Saenz A., Hood S., and Barber G.G. Pharmacological management of intermittent claudication: a meta-analysis of randomized trials. Drugs 59 (2000) 1057-1070
4. Ward A., and Chissold S.P. Pentoxyfilline: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 34 (1987) 50-97
5. Davidson A., and Diamond B. Autoimmune diseases. N. Engl. J. Med. 345 (2001) 340-350
6. Anaya J.M., and Espinoza L.R. Phosphodiesterase inhibitor pentoxifylline: an antiinflammatory immunomodulatory drug potentially useful in some rheumatic diseases. J. Rheumatol. 22 (1995) 595-599
7. Maksymowych W.P., Avina-Zubieta A., Luong M.H., and Russel A.S. An open study of pentoxifylline in the treatment of severe refractory rheumatoid arthritis. J. Rheumatol. 22 (1995) 625-629
8. Kiely P.D.W., Johnson D., and Bourke B.E. An open study of oxpentifylline in early rheumatoid arthritis. Br. J. Rheumatol. 37 (1998) 1033-1035
9. Huizinga T.W., Dijkmans B.A., van der Velde E.A., van de Pouw Kraan T.C., Verweij C.L., and Breedveld F.C. An open study of pentoxifylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis. Ann. Rheum. Dis. 55 (1996) 833-836
10. Houssiau F.A. Management of lupus nephritis: an update. J. Am. Soc. Nephrol. 15 (2004) 2694-2704
11. Navarro J.F., and Mora C. Antiproteinuric effect of pentoxifylline in patients with diabetic nephropathy. Diab. Care 22 (1999) 1006-1007
12. Ducloux D., Bresson-Vautrin C., and Chalopin J. Use of pentoxifylline in membranous nephropathy. Lancet 357 (2001) 1672-1673
13. Galindo-Rodriguez G., Bustamante R., Esquivel-Nava G., Salazar-Exaire D., Vela-Oleda J., Vadillo-Buenfil M., et al. Pentoxifylline in the treatment of refractory nephrotic syndrome secondary to lupus nephritis. J. Rheumatol. 30 (2003) 2382-2384
14. Yasui K., Ohta K., Kobayashi M., Aizawa T., and Komiyama A. Successful treatment of Behçet disease with pentoxifylline. Ann. Intern. Med. 124 (1996) 891-893
15. Liang G.C., and Chang E.M. Pentoxifylline use for Behçet's disease. Adv. Exp. Biol. Med. 528 (2003) 591-594
16. Pizzaro A., Navarro A., Fonseca E., Vidaurrazaga C., and Herranz P. Treatment of recurrent aphthous stomatitis with pentoxifylline. Br. J. Dermatol. 133 (1995) 659-660
17. Wahba-Yahav A.V. Pentoxifylline in intractable recurrent aphthous stomatitis : an open trial. J. Am. Acad. Dermatol. 33 (1995) 680-682
18. Nürnberg W., Grabbe J., and Czarnetzki B.M. Synergistic effects of pentoxifylline and dapsone in leucocytoclasic vasculitis. Lancet 343 (1994) 491
19. Nürnberg W., Grabbe J., and Czarnetzki B.M. Urticarial vasculitis syndrome effectively treated with dapsone and pentoxifylline. Acta Dermatol. Venereol. 75 (1995) 54-56
20. Furukawa S., Matsubara T., Umezana Y., Motohashi T., Ino T., and Yabuta K. Pentoxifylline and intravenous gammaglobulin combination therapy for acute Kawasaki disease. Eur. J. Pediatr. 153 (1994) 663-667
21. Calderon M.J., Landa M., Aguirre A., and Diaz-Perez J.L. Successful treatment of cutaneous PAN with pentoxifylline. Br. J. Dermatol. 128 (1993) 706-708
22. Baughmann R.P., Lower E.E., and du Bois R.M. Sarcoidosis. Lancet 361 (2003) 1111-1118
23. Marques L.J., Zheng L., Poulakis N., Guzman J., and Costabel U. Pentoxifylline inhibits TNF-alpha production from alveolar human macrophages. Am. J. Respir. Crit. Care Med. 159 (1999) 508-511
24. Zabel P., Entzian P., Dalhoff K., and Schlaak M. Pentoxifylline in treatment of sarcoidosis. Am. J. Respir. Crit. Care Med. 155 (1997) 1665-1669
25. Reimund J.M., Dumont S., Muller C.D., Kenney J.S., Kedinger M., Baumann R., et al. In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease. Gut 40 (1997) 475-480
26. Bauditz J., Haemling J., Ortner M., Lochs H., Raedler A., and Schreiber S. Treatment with Tumor Necrosis Factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease. Gut 40 (1997) 470-474
27. Akriviadis E., Botla D., Briggs W., Han S., Reynolds T., and Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 119 (2000) 1635-1640
28. Satapathy S.K., Garg S., Chauhan R., Sakhuja P., Malhotra V., Sharma B.C., et al. Beneficial effects of Tumor Necrosis Factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 99 (2004) 1946-1952
29. Adams L.A., Zein C.O., Angulo P., and Lindor K.D. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am. J. Gastroenterol. 99 (2004) 2365-2368
30. Jull A., Waters J., and Arroll B. Pentoxifylline for treatment of venous leg ulcers: a systematic review. Lancet 359 (2002) 1550-1554
31. Raza A., Qawi H., Lisak L., Andric T., Dar S., Andrews C., et al. Patients with myelodysplastic syndromes benefit from palliative theapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone. Blood 95 (2000) 1580-1587
32. Staubach K.H., Schröder J., Stüber F., Gehrke K., Traumann E., and Zabel P. Effect of pentoxifylline in severe sepsis. Arch. Surg. 133 (1998) 94-100
33. e ed (2000), Elsevier, Amsterdam 629-637
34. Mathian A., Amoura Z., and Piette J.C. Pentoxifylline-induced aseptic meningitidis in a patient with mixed connective tissue disease. Neurology 59 (2002) 1468-1469
35. Lin S.L., Chen Y.M., Chiang W.C., Tsai T.J., and Chen W.Y. Pentoxifylline: a potential therapy for chronic kidney disease. Nephrol. 9 (2004) 198-204